Cyclin-dependent Kinase Inhibitor in Acute Renal Failure
Cyclin-dependent Kinase Inhibitor in Acute Renal Failure
批准号:
8183462
负责人:
PETER M. PRICE
金额:
$5.4万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-08-01 至 2012-01-31
关键词:
AcuteAcute Kidney FailureAcute Renal Failure with Renal Papillary NecrosisAddressAffectApoptosisBindingCell CycleCell Cycle ProgressionCell DeathCellsCessation of lifeCisplatinCritical IllnessCyclin-Dependent Kinase InhibitorDevelopmentDiseaseDominant-Negative MutationEnzyme InhibitionEnzyme Inhibitor DrugsEnzyme InhibitorsEnzymesFamily memberFinancial costGoalsHumanIn VitroIncidenceInjuryInterventionIschemiaKidneyKidney FailureLeadLifeLong-Term EffectsMethodsMitochondriaModelingModificationMolecularMorbidity - disease rateMouse StrainsMusNatural regenerationNecrosisOrgan failurePathway interactionsPatient CarePatientsPersonal SatisfactionPhosphorylationPhosphotransferasesPopulationPost-Translational Protein ProcessingProcessProteinsProximal Kidney TubulesRecoveryReperfusion TherapyReportingResistanceRisk FactorsRoleSyndromeTimeToxic effectToxinTransgenesTransgenic MiceTransgenic OrganismsTranslatingUp-Regulationbasecell injurycellular transductioncostcytotoxicitydisabilityhuman CDK2 proteinin vivoinhibitor/antagonistinjuredkidney cellmortalitymutantnephrotoxicitynoveloncoprotein p21preventprotein protein interactionresponsetranslational approach
中文摘要
描述(申请人提供):我们的长期目标是预防/治疗急性肾损伤。我们正在使用顺铂毒性作为肾脏损伤的模型,在体外使用培养的小鼠肾近端小管细胞,并在体内使用野生型和转基因小鼠。我们已经证实,抑制细胞周期相关的酶,细胞周期蛋白依赖性激酶-2(CDK2),在体外保护细胞毒性,并在体内保护顺铂引起的肾脏损伤。基于这些发现,我们培育了两个转基因小鼠品系,由于特异性CDK2抑制,它们对顺铂诱导的急性肾损伤具有抵抗力。我们发现,细胞死亡的几条途径依赖于CDK2的活性,并有助于顺铂的细胞毒性。我们假设,细胞死亡由顺铂激活,并依赖于CDK2激酶活性,可能可以通过交叉途径而不是平行途径来解释。现在我们发现,作为对顺铂的反应,CDK2磷酸化了两种蛋白,p21和BclxL,这两种蛋白可以直接或间接地影响细胞死亡途径。在我们的第一个特定目标中,我们将调查这些蛋白质是否提供了细胞周期和细胞死亡的交叉点。我们假设抑制CDK2将是预防AKI的有效的短期和长期策略。我们最近开发的转基因小鼠诱导了p21或dN-CDK2的表达,使其免受顺铂肾毒性的保护,证实了这一假设的前半部分。我们假设的后半部分将在第二个具体目标中解决,这将确定抑制CDK2是否只是推迟肾毒性,以及CDK2抑制和顺铂暴露是否会对肾脏恢复造成长期影响。
公共卫生相关性:急性肾损伤(AKI)是一种常见疾病,影响多达5%的住院患者。尽管我们对AKI的发病率和后果有了更多的了解,但危重患者中与AKI相关的发病率和死亡率仍保持在50%以上。AKI是导致死亡和残疾的多器官衰竭的独立危险因素。据估计,AKI每年的财务成本为80亿美元,或者说每个节省下来的生命年大约13万美元。在我们了解细胞损伤和恢复的细胞和分子机制之前,这种高死亡率和相关成本不太可能降低。我们发现,细胞周期酶抑制剂在体外可以完全保护肾细胞免受顺铂的细胞毒作用,并在体内显着减少AKI的形态和功能。我们已经开发出对AKI具有抵抗力的转基因小鼠。保护的机制及其在体内的使用将被研究。我们的建议将导致开发可用于预防AKI的试剂,这将直接影响患者的护理和福祉。
英文摘要
DESCRIPTION (provided by applicant): Our long-term goal is to prevent/treat acute kidney injury. We are using cisplatin toxicity as a model of renal injury, in vitro using cultured mouse kidney proximal tubule cells, and in vivo using wild-type and transgenic mice. We have established that inhibition of a cell cycle-associated enzyme, cyclin-dependent kinase-2 (Cdk2), protect from cytotoxicity in vitro and protects from kidney injury in vivo caused by cisplatin administration. Based on these findings, we developed two transgenic mouse strains resistant to cisplatin-induced acute renal injury because of specific cdk2 inhibition. We found that several pathways of cell death were dependent on Cdk2 activity and contribute to cisplatin cytotoxicity. We hypothesize that cell death activated by cisplatin and dependent on Cdk2 kinase activity can likely be explained by intersecting rather than parallel pathways. Now we find that in response to cisplatin, Cdk2 phosphorylates two proteins, p21 and Bcl xL, that directly and indirectly could have effects on cell death pathways. In our first specific aim we will investigate whether these proteins provide the intersections of cell cycle and cell death. We hypothesize that Cdk2 inhibition would be an effective short- and long-term strategy to prevent AKI. Our recently developed transgenic mice in which induced expression of either p21 or DN-Cdk2 protected from cisplatin nephrotoxicity confirmed the first half of this hypothesis. The second half of our hypothesis will be addressed in this second specific aim, which will determine whether Cdk2inhibition merely delays nephrotoxicity and whether Cdk2 inhibition and cisplatin exposure causes longer-term effects on kidney recovery.
PUBLIC HEALTH RELEVANCE: Acute kidney injury (AKI) is a common disorder affecting up to 5% of hospitalized patients. Despite our increased understanding of the incidence and consequences of AKI, morbidity and mortality associated with this syndrome in critically ill patients has remained above 50%. AKI is an independent risk factor in the setting of multi organ failure leading to death and disability. The financial costs of AKI are estimated to be 8 billion dollars per year, or about $130,000 per life-year saved. It is unlikely that this high mortality and associated cost will be reduced until we understand the cellular and molecular mechanisms of cell injury and recovery. We found that cell cycle enzyme inhibitors will totally protect kidney cells in vitro from cisplatin cytotoxicity and significantly diminish morphologic and functional AKI in vivo. We have developed transgenic mice that are resistant to AKI. The mechanism of protection and its use in vivo will be investigated. Our proposal will lead to the development of agents that can be used to prevent AKI, which will directly impact patient care and well-being.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Biologic Effects of Cdk2 Substrate Phosphorylation on Acute Kidney Injury
-
批准号:8597416
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:PETER M. PRICE
-
依托单位:
Biologic Effects of Cdk2 Substrate Phosphorylation on Acute Kidney Injury
-
批准号:8260111
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:PETER M. PRICE
-
依托单位:
Biologic Effects of Cdk2 Substrate Phosphorylation on Acute Kidney Injury
-
批准号:8141668
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:PETER M. PRICE
-
依托单位:
Biologic Effects of Cdk2 Substrate Phosphorylation on Acute Kidney Injury
-
批准号:8398965
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:PETER M. PRICE
-
依托单位:
CYCLIN DEPENDENT KINASE INHIBITOR IN ACUTE RENAL FAILURE
-
批准号:6177901
-
项目类别:
-
资助金额:$17.54万
-
财政年份:1998
-
负责人:PETER M. PRICE
-
依托单位:
Cyclin-dependent Kinase Inhibitor in Acute Renal Failure
-
批准号:8477648
-
项目类别:
-
资助金额:$22.95万
-
财政年份:1998
-
负责人:PETER M. PRICE
-
依托单位:
Cyclin-dependent Kinase Inhibitor In Acute Renal Failure
-
批准号:7766238
-
项目类别:
-
资助金额:$21.9万
-
财政年份:1998
-
负责人:PETER M. PRICE
-
依托单位:
CYCLIN DEPENDENT KINASE INHIBITOR IN ACUTE RENAL FAILURE
-
批准号:6381236
-
项目类别:
-
资助金额:$18.07万
-
财政年份:1998
-
负责人:PETER M. PRICE
-
依托单位:
Cyclin-dependent Kinase Inhibitor In Acute Renal Failure
-
批准号:7045861
-
项目类别:
-
资助金额:$23.25万
-
财政年份:1998
-
负责人:PETER M. PRICE
-
依托单位:
Cyclin-dependent Kinase Inhibitor In Acute Renal Failure
-
批准号:7569026
-
项目类别:
-
资助金额:$22.12万
-
财政年份:1998
-
负责人:PETER M. PRICE
-
依托单位:
Cyclin-dependent Kinase Inhibitor In Acute Renal Failure
-
批准号:7379947
-
项目类别:
-
资助金额:$22.12万
-
财政年份:1998
-
负责人:PETER M. PRICE
-
依托单位:
Cyclin-dependent Kinase Inhibitor in Acute Renal Failure
-
批准号:8546326
-
项目类别:
-
资助金额:$25.86万
-
财政年份:1998
-
负责人:PETER M. PRICE
-
依托单位:
CYCLIN DEPENDENT KINASE INHIBITOR IN ACUTE RENAL FAILURE
-
批准号:6133918
-
项目类别:
-
资助金额:$7.94万
-
财政年份:1998
-
负责人:PETER M. PRICE
-
依托单位:
Cyclin-dependent Kinase Inhibitor in Acute Renal Failure
-
批准号:8337721
-
项目类别:
-
资助金额:$26.8万
-
财政年份:1998
-
负责人:PETER M. PRICE
-
依托单位:
CYCLIN DEPENDENT KINASE INHIBITOR IN ACUTE RENAL FAILURE
-
批准号:2906291
-
项目类别:
-
资助金额:$17.03万
-
财政年份:1998
-
负责人:PETER M. PRICE
-
依托单位:
Cyclin-dependent Kinase Inhibitor In Acute Renal Failure
-
批准号:7185114
-
项目类别:
-
资助金额:$22.57万
-
财政年份:1998
-
负责人:PETER M. PRICE
-
依托单位:
CYCLIN DEPENDENT KINASE INHIBITOR IN ACUTE RENAL FAILURE
-
批准号:2689287
-
项目类别:
-
资助金额:$13.44万
-
财政年份:1998
-
负责人:PETER M. PRICE
-
依托单位:
海外基金